XLO (Xilio Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on XLO (Xilio Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

XLO

Xilio Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Nov 7, 2025
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2025
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
Oct 30, 2025
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Oct 3, 2025
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Sep 9, 2025
Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024)
Aug 16, 2025
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Aug 14, 2025
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Jun 10, 2025
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Jun 2, 2025
Xilio Therapeutics Announces Proposed Public Offering
Jun 2, 2025
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
May 8, 2025
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2025

Reviews